{
    "info": {
        "nct_id": "NCT05588609",
        "official_title": "A Phase 2 Study Evaluating Activity of Zenocutuzumab (MCLA-128) in Patients With or Without Molecularly Defined Cancers",
        "inclusion_criteria": "(Groups A, B)\n\n1. Signed informed consent before initiation of any study procedures.\n2. Age ≥ 18 years at signature of informed consent.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n4. Estimated life expectancy of ≥ 12 weeks.\n5. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA).\n6. Adequate organ function:\n\n   * Absolute neutrophil count ≥ 1.5 × 109/L.\n   * Hemoglobin ≥ 9 g/dL.\n   * Platelets ≥ 100 × 109/L.\n   * Serum calcium within normal ranges (or corrected with supplements).\n   * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed).\n   * Total bilirubin ≤ 1.5 × ULN (in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed).\n   * Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula (Appendix D).\n   * Serum albumin > 3.0 g/dL.\n7. Availability of a representative tumor specimen, either a formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF]) or an FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment. A fresh FFPE sample is preferred.\n8. Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.\n\nInclusion Criteria: (Group A Only)\n\nA1. Have histologically confirmed locally advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA. A2. Have received prior standard therapy appropriate for the tumor type and disease or must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator or have no satisfactory available treatment options. A3. Have at least 1 measurable lesion per RECIST v1.1. A4. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.\n\nInclusion Criteria: (Group B Only) B1. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. B2. Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). B3. Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening. B4. Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening. B5. Progressive disease by PCWG3 criteria B6. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "(Groups A, B)\n\n1. Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.\n2. Previous exposure to anti-HER3-directed therapies.\n3. Known leptomeningeal involvement.\n4. Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks before study entry.\n5. Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day).\n6. Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) or unstable angina.\n7. History of congestive heart failure Class II-IV by New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia).\n8. History of myocardial infarction within 6 months of study entry.\n9. History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.\n10. Current serious illness or medical conditions including, but not limited to uncontrolled active infection, and clinically significant pulmonary, metabolic, or psychiatric disorders.\n11. Patients with the following known infectious diseases:\n\n    * Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment.\n    * Known positive test for hepatitis C virus (HCV) RNA.\n12. Known human immunodeficiency virus (HIV)-positive patients unless the CD4+ count is ≥ 300/μL, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy.\n\nExclusion Criteria: (Group A) A1. Patients previously exposed to afatinib. A2. History of interstitial lung disease (ILD), ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis), or radiation pneumonia requiring steroid therapy.\n\nExclusion Criteria: (Group B) B1. More than 2 lines of a second-generation hormonal agent for metastatic disease.\n\nB2. More than 2 lines of systemic chemotherapy for metastatic disease. B3. Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations). B4. A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "6. Adequate organ function:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin ≤ 1.5 × ULN (in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed).",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 × ULN",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in case of Gilbert disease, total bilirubin ≤ 3 × ULN will be allowed",
                    "criterion": "total bilirubin in case of Gilbert disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Signed informed consent before initiation of any study procedures.",
            "criterions": [
                {
                    "exact_snippets": "Signed informed consent before initiation of any study procedures.",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "before initiation of any study procedures"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria: (Group A Only)",
            "criterions": [
                {
                    "exact_snippets": "(Group A Only)",
                    "criterion": "study group assignment",
                    "requirements": [
                        {
                            "requirement_type": "group",
                            "expected_value": "A"
                        }
                    ]
                }
            ]
        },
        {
            "line": "(Groups A, B)",
            "criterions": [
                {
                    "exact_snippets": "(Groups A, B)",
                    "criterion": "study group assignment",
                    "requirements": [
                        {
                            "requirement_type": "group membership",
                            "expected_value": [
                                "A",
                                "B"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum calcium within normal ranges (or corrected with supplements).",
            "criterions": [
                {
                    "exact_snippets": "Serum calcium within normal ranges (or corrected with supplements)",
                    "criterion": "serum calcium",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal ranges"
                        },
                        {
                            "requirement_type": "correction",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum albumin > 3.0 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Serum albumin > 3.0 g/dL",
                    "criterion": "serum albumin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 3.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin ≥ 9 g/dL.",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin ≥ 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula (Appendix D).",
            "criterions": [
                {
                    "exact_snippets": "Estimated glomerular filtration rate of > 30 mL/min based on the Cockroft-Gault formula",
                    "criterion": "estimated glomerular filtration rate",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 30,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "calculation method",
                            "expected_value": "Cockroft-Gault formula"
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram (ECHO) or multi-gated acquisition scan (MUGA).",
            "criterions": [
                {
                    "exact_snippets": "Left ventricular ejection fraction (LVEF) ≥ 50%",
                    "criterion": "left ventricular ejection fraction (LVEF)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "echocardiogram (ECHO)",
                                "multi-gated acquisition scan (MUGA)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Estimated life expectancy of ≥ 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Estimated life expectancy of ≥ 12 weeks.",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed).",
            "criterions": [
                {
                    "exact_snippets": "Alanine aminotransferase (ALT) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ALT ... ≤ 5 × ULN will be allowed)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aspartate aminotransferase (AST) ... ≤ 2.5 × upper limit of normal (ULN) (in case of liver involvement by malignancy, ... AST ≤ 5 × ULN will be allowed)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "in case of liver involvement by malignancy, ALT/AST ≤ 5 × ULN will be allowed",
                    "criterion": "ALT and AST levels in case of liver involvement by malignancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Availability of a representative tumor specimen, either a formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF]) or an FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment. A fresh FFPE sample is preferred.",
            "criterions": [
                {
                    "exact_snippets": "Availability of a representative tumor specimen",
                    "criterion": "tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "formalin-fixed paraffin embedded (FFPE) de novo (ie, obtained up to 2 months before signing of the informed consent form [ICF])",
                    "criterion": "FFPE de novo tumor specimen",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "before signing of the informed consent form"
                        }
                    ]
                },
                {
                    "exact_snippets": "FFPE archival tumor sample, preferably collected within 2 years of the start of study treatment",
                    "criterion": "FFPE archival tumor sample",
                    "requirements": [
                        {
                            "requirement_type": "recency (preferred)",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "timing_reference",
                            "expected_value": "before start of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "A fresh FFPE sample is preferred",
                    "criterion": "fresh FFPE sample",
                    "requirements": [
                        {
                            "requirement_type": "preference",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Inclusion Criteria: (Group B Only) B1. Histologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features. B2. Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). B3. Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening. B4. Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening. B5. Progressive disease by PCWG3 criteria B6. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed adenocarcinoma of the prostate",
                    "criterion": "adenocarcinoma of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                },
                {
                    "exact_snippets": "without neuroendocrine differentiation or small cell features",
                    "criterion": "neuroendocrine differentiation or small cell features",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Metastatic disease documented by at least 2 bone lesions on whole body bone scintigraphy",
                    "criterion": "bone metastases",
                    "requirements": [
                        {
                            "requirement_type": "number of lesions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lesions"
                            }
                        },
                        {
                            "requirement_type": "documentation method",
                            "expected_value": "whole body bone scintigraphy"
                        }
                    ]
                },
                {
                    "exact_snippets": "soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI)",
                    "criterion": "soft tissue disease",
                    "requirements": [
                        {
                            "requirement_type": "documentation method",
                            "expected_value": [
                                "computed tomography (CT) scan",
                                "magnetic resonance imaging (MRI)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Ongoing androgen deprivation with a serum testosterone level ≤ 1.73 nmol/L (≤ 50 ng/dL) at Screening",
                    "criterion": "serum testosterone level",
                    "requirements": [
                        {
                            "requirement_type": "value at Screening",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.73,
                                "unit": "nmol/L"
                            }
                        },
                        {
                            "requirement_type": "androgen deprivation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Current ongoing therapy with a next-generation AR signaling inhibitor (enzalutamide or abiraterone) started at least 90 days before Screening",
                    "criterion": "next-generation AR signaling inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "current therapy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug",
                            "expected_value": [
                                "enzalutamide",
                                "abiraterone"
                            ]
                        },
                        {
                            "requirement_type": "duration before Screening",
                            "expected_value": {
                                "operator": ">=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Progressive disease by PCWG3 criteria",
                    "criterion": "progressive disease",
                    "requirements": [
                        {
                            "requirement_type": "definition",
                            "expected_value": "PCWG3 criteria"
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption",
                    "criterion": "gastrointestinal conditions jeopardizing intestinal absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Age ≥ 18 years at signature of informed consent.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "A1. Have histologically confirmed locally advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA. A2. Have received prior standard therapy appropriate for the tumor type and disease or must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator or have no satisfactory available treatment options. A3. Have at least 1 measurable lesion per RECIST v1.1. A4. Able to swallow oral medications and absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption.",
            "criterions": [
                {
                    "exact_snippets": "histologically confirmed locally advanced, unresectable, or metastatic NSCLC",
                    "criterion": "NSCLC disease status",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histology"
                        },
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "locally advanced",
                                "unresectable",
                                "metastatic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "harboring an NRG1 gene fusion detected by DNA- or RNA-based next generation sequencing in a tumor sample or in plasma-cell free DNA",
                    "criterion": "NRG1 gene fusion",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detection method",
                            "expected_value": [
                                "DNA-based next generation sequencing",
                                "RNA-based next generation sequencing"
                            ]
                        },
                        {
                            "requirement_type": "sample type",
                            "expected_value": [
                                "tumor sample",
                                "plasma-cell free DNA"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Have received prior standard therapy appropriate for the tumor type and disease",
                    "criterion": "prior standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must be unlikely to tolerate or derive clinically meaningful benefit from appropriate standard of care therapy in the opinion of the Investigator",
                    "criterion": "tolerance or benefit from standard of care therapy",
                    "requirements": [
                        {
                            "requirement_type": "tolerance or benefit",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "assessment by",
                            "expected_value": "Investigator"
                        }
                    ]
                },
                {
                    "exact_snippets": "have no satisfactory available treatment options",
                    "criterion": "satisfactory available treatment options",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 1 measurable lesion per RECIST v1.1",
                    "criterion": "measurable lesion count",
                    "requirements": [
                        {
                            "requirement_type": "count",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lesion"
                            }
                        },
                        {
                            "requirement_type": "measurement criteria",
                            "expected_value": "RECIST v1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "Able to swallow oral medications",
                    "criterion": "ability to swallow oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "absence of gastrointestinal conditions (eg, malabsorption, resection) deemed to jeopardize intestinal absorption",
                    "criterion": "gastrointestinal conditions affecting absorption",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "effect",
                            "expected_value": "jeopardize intestinal absorption"
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Sexually active male and female patients of childbearing potential must agree to use contraceptive measures.",
            "criterions": [
                {
                    "exact_snippets": "Sexually active male and female patients of childbearing potential",
                    "criterion": "sexually active patients of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sexually active",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must agree to use contraceptive measures",
                    "criterion": "contraceptive use agreement",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use contraception",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "3. Known leptomeningeal involvement.",
            "criterions": [
                {
                    "exact_snippets": "Known leptomeningeal involvement",
                    "criterion": "leptomeningeal involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "knowledge_status",
                            "expected_value": "known"
                        }
                    ]
                }
            ]
        },
        {
            "line": "(Groups A, B)",
            "criterions": [
                {
                    "exact_snippets": "(Groups A, B)",
                    "criterion": "study group assignment",
                    "requirements": [
                        {
                            "requirement_type": "group membership",
                            "expected_value": [
                                "A",
                                "B"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Participation in another interventional clinical trial or treatment with any investigational drug within 4 weeks before study entry.",
            "criterions": [
                {
                    "exact_snippets": "Participation in another interventional clinical trial",
                    "criterion": "participation in another interventional clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "treatment with any investigational drug within 4 weeks before study entry",
                    "criterion": "treatment with investigational drug",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Central nervous system metastases that are untreated or symptomatic, or require radiation, surgery, or continued steroid therapy to control symptoms within 14 days of study entry.",
            "criterions": [
                {
                    "exact_snippets": "Central nervous system metastases that are untreated",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that are ... symptomatic",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that ... require radiation ... to control symptoms within 14 days of study entry",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "need for radiation to control symptoms within 14 days of study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that ... require ... surgery ... to control symptoms within 14 days of study entry",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "need for surgery to control symptoms within 14 days of study entry",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Central nervous system metastases that ... require ... continued steroid therapy to control symptoms within 14 days of study entry",
                    "criterion": "central nervous system metastases",
                    "requirements": [
                        {
                            "requirement_type": "need for continued steroid therapy to control symptoms within 14 days of study entry",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Previous exposure to anti-HER3-directed therapies.",
            "criterions": [
                {
                    "exact_snippets": "Previous exposure to anti-HER3-directed therapies",
                    "criterion": "exposure to anti-HER3-directed therapies",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. History of congestive heart failure Class II-IV by New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia).",
            "criterions": [
                {
                    "exact_snippets": "History of congestive heart failure Class II-IV by New York Heart Association criteria",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmia requiring treatment (except atrial fibrillation, or paroxysmal supraventricular tachycardia)",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "requires treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "arrhythmia type exclusion",
                            "expected_value": [
                                "atrial fibrillation",
                                "paroxysmal supraventricular tachycardia"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg) or unstable angina.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled hypertension (systolic blood pressure > 150 mmHg and/or diastolic blood pressure > 100 mmHg)",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "systolic blood pressure > 150 mmHg",
                    "criterion": "systolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "diastolic blood pressure > 100 mmHg",
                    "criterion": "diastolic blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "angina",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known positive test for hepatitis C virus (HCV) RNA.",
            "criterions": [
                {
                    "exact_snippets": "Known positive test for hepatitis C virus (HCV) RNA",
                    "criterion": "hepatitis C virus (HCV) RNA test",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "positive"
                        },
                        {
                            "requirement_type": "knowledge status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria: (Group B) B1. More than 2 lines of a second-generation hormonal agent for metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "More than 2 lines of a second-generation hormonal agent for metastatic disease",
                    "criterion": "lines of second-generation hormonal agent for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Exclusion Criteria: (Group A) A1. Patients previously exposed to afatinib. A2. History of interstitial lung disease (ILD), ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis), or radiation pneumonia requiring steroid therapy.",
            "criterions": [
                {
                    "exact_snippets": "Patients previously exposed to afatinib",
                    "criterion": "afatinib exposure",
                    "requirements": [
                        {
                            "requirement_type": "history of exposure",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "History of interstitial lung disease (ILD)",
                    "criterion": "interstitial lung disease (ILD)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ILD-like adverse reactions (such as lung infiltration, pneumonitis, acute respiratory distress syndrome, allergic alveolitis)",
                    "criterion": "ILD-like adverse reactions",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation pneumonia requiring steroid therapy",
                    "criterion": "radiation pneumonia requiring steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day).",
            "criterions": [
                {
                    "exact_snippets": "Chronic use of high-dose oral corticosteroid therapy (> 10 mg of prednisone- equivalent a day)",
                    "criterion": "oral corticosteroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "chronic use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg of prednisone-equivalent per day"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "B2. More than 2 lines of systemic chemotherapy for metastatic disease. B3. Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations). B4. A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide.",
            "criterions": [
                {
                    "exact_snippets": "More than 2 lines of systemic chemotherapy for metastatic disease",
                    "criterion": "lines of systemic chemotherapy for metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Patients with only nonmeasurable lesions other than bone metastasis (eg, pleural effusion, ascites, other visceral locations)",
                    "criterion": "nonmeasurable lesions (excluding bone metastasis)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "location",
                            "expected_value": [
                                "pleural effusion",
                                "ascites",
                                "other visceral locations"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "A history of seizure or any condition predisposing patient to seizure within 12 months before study treatment, including history of unexplained loss of consciousness or transient ischemic attack, for patients receiving enzalutamide",
                    "criterion": "history of seizure or condition predisposing to seizure",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "predisposing_condition",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "receiving_enzalutamide",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of unexplained loss of consciousness or transient ischemic attack",
                    "criterion": "history of unexplained loss of consciousness or transient ischemic attack",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "receiving_enzalutamide",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "* Absolute neutrophil count ≥ 1.5 × 109/L.",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count ≥ 1.5 × 10^9/L.",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets ≥ 100 × 109/L.",
            "criterions": [
                {
                    "exact_snippets": "Platelets ≥ 100 × 10^9/L.",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "10^9/L"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_exclusion": [
        {
            "line": "8. History of myocardial infarction within 6 months of study entry.",
            "criterions": []
        },
        {
            "line": "10. Current serious illness or medical conditions including, but not limited to uncontrolled active infection, and clinically significant pulmonary, metabolic, or psychiatric disorders.",
            "criterions": []
        },
        {
            "line": "9. History of prior or concomitant malignancies (other than excised nonmelanoma skin cancer, cured in situ cervical carcinoma, or low-grade Ta or T1 urothelial carcinoma of the bladder that has undergone potentially curative therapy) within 3 years of study entry.",
            "criterions": []
        },
        {
            "line": "* Known active hepatitis B infection (hepatitis B surface antigen [HBsAg] positive) without receiving antiviral treatment.",
            "criterions": []
        },
        {
            "line": "11. Patients with the following known infectious diseases:",
            "criterions": []
        },
        {
            "line": "12. Known human immunodeficiency virus (HIV)-positive patients unless the CD4+ count is ≥ 300/μL, viral load is undetectable, and the patient is currently receiving highly active antiretroviral therapy.",
            "criterions": []
        }
    ],
    "failed_miscellaneous": []
}